;PMID: 2657575
;source_file_1241.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..30] = [t:0..30]
;1)sentence:[e:35..90] = [t:35..90]
;2)section:[e:94..130] = [t:94..130]
;3)section:[e:134..236] = [t:134..236]
;4)sentence:[e:240..412] = [t:240..412]
;5)sentence:[e:413..578] = [t:413..578]
;6)sentence:[e:579..629] = [t:579..629]
;7)sentence:[e:630..823] = [t:630..823]
;8)sentence:[e:824..929] = [t:824..929]
;9)sentence:[e:930..1164] = [t:930..1164]
;10)sentence:[e:1165..1381] = [t:1165..1381]
;11)sentence:[e:1382..1657] = [t:1382..1657]
;12)section:[e:1661..1705] = [t:1661..1705]

;section 0 Span:0..30
;Oncogene  1989 May;4(5):609-14
(SEC
  (FRAG (IN:[0..8] Oncogene) (CD:[10..14] 1989) (NNP:[15..18] May)
        (CD:[18..21] ;4-LRB-) (CD:[21..22] 5) (-RRB-:[22..23] -RRB-)
        (CD:[23..27] :609) (::[27..28] -) (CD:[28..30] 14)))

;sentence 1 Span:35..90
;Mechanisms of ras mutation in myelodysplastic syndrome.
;[49..52]:gene-rna:"ras"
;[65..89]:malignancy:"myelodysplastic syndrome"
(SENT
  (NP-HLN
    (NP (NNS:[35..45] Mechanisms))
    (PP (IN:[46..48] of)
      (NP (NN:[49..52] ras) (NN:[53..61] mutation)))
    (PP (IN:[62..64] in)
      (NP (JJ:[65..80] myelodysplastic) (NN:[81..89] syndrome)))
    (.:[89..90] .)))

;section 2 Span:94..130
;Yunis JJ, Boot AJ, Mayer MG, Bos JL.
(SEC
  (FRAG (NNP:[94..99] Yunis) (NNP:[100..102] JJ) (,:[102..103] ,)
        (NNP:[104..108] Boot) (NNP:[109..111] AJ) (,:[111..112] ,)
        (NNP:[113..118] Mayer) (NNP:[119..121] MG) (,:[121..122] ,)
        (NNP:[123..126] Bos) (NNP:[127..130] JL.)))

;section 3 Span:134..236
;Department of Laboratory Medicine and Pathology, University of Minnesota
;Medical  School, Minneapolis.
(SEC
  (FRAG (NNP:[134..144] Department) (IN:[145..147] of)
        (NNP:[148..158] Laboratory) (NNP:[159..167] Medicine)
        (CC:[168..171] and) (NNP:[172..181] Pathology) (,:[181..182] ,)
        (NNP:[183..193] University) (IN:[194..196] of)
        (NNP:[197..206] Minnesota) (NNP:[207..214] Medical)
        (NNP:[216..222] School) (,:[222..223] ,) (NNP:[224..235] Minneapolis)
        (.:[235..236] .)))

;sentence 4 Span:240..412
;Using synthetic oligonucleotide hybridization, we have found a ras mutation
;in  11 of 27 patients (41%) with primary or non-therapy related
;myelodysplastic  syndrome (MDS).
;[303..306]:gene-rna:"ras"
;[380..405]:malignancy:"myelodysplastic  syndrome"
;[407..410]:malignancy:"MDS"
(SENT
  (S
    (S-MNR
      (NP-SBJ (-NONE-:[240..240] *))
      (VP (VBG:[240..245] Using)
        (NP (JJ:[246..255] synthetic) (NN:[256..271] oligonucleotide)
            (NN:[272..285] hybridization))))
    (,:[285..286] ,)
    (NP-SBJ (PRP:[287..289] we))
    (VP (VBP:[290..294] have)
      (VP (VBN:[295..300] found)
        (NP (DT:[301..302] a) (NN:[303..306] ras) (NN:[307..315] mutation))
        (PP-LOC (IN:[316..318] in)
          (NP
            (NP (CD:[320..322] 11))
            (PP (IN:[323..325] of)
              (NP
                (NP (CD:[326..328] 27) (NNS:[329..337] patients)
                  (PRN (-LRB-:[338..339] -LRB-)
                    (NP (CD:[339..341] 41) (NN:[341..342] %))
                    (-RRB-:[342..343] -RRB-)))
                (PP (IN:[344..348] with)
                  (NP
                    (NP (JJ:[349..356] primary)
                      (NML-1 (-NONE-:[356..356] *P*)))
                    (CC:[357..359] or)
                    (NP
                      (ADJP (AFX:[360..363] non) (HYPH:[363..364] -)
                        (ADJP (NN:[364..371] therapy) (VBN:[372..379] related)))
                      (NML-1
                        (NML (JJ:[380..395] myelodysplastic)
                             (NN:[397..405] syndrome))
                        (NML (-LRB-:[406..407] -LRB-) (NN:[407..410] MDS)
                             (-RRB-:[410..411] -RRB-))))))))))))
    (.:[411..412] .)))

;sentence 5 Span:413..578
;This high incidence of mutation, mainly of the N-ras oncogene,  was generally
;found in patients with disease progression to acute leukemia (8 of  11
;patients = 73%).
;[460..465]:gene-rna:"N-ras"
;[537..551]:malignancy:"acute leukemia"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[413..417] This) (JJ:[418..422] high) (NN:[423..432] incidence))
      (PP (IN:[433..435] of)
        (NP (NN:[436..444] mutation))))
    (,:[444..445] ,)
    (PP
      (ADVP (RB:[446..452] mainly))
      (IN:[453..455] of)
      (NP (DT:[456..459] the) (NN:[460..465] N-ras) (NN:[466..474] oncogene)))
    (,:[474..475] ,)
    (VP (VBD:[477..480] was)
      (ADVP (RB:[481..490] generally))
      (VP (VBN:[491..496] found)
        (NP-1 (-NONE-:[496..496] *))
        (PP-LOC (IN:[497..499] in)
          (NP
            (NP (NNS:[500..508] patients))
            (PP (IN:[509..513] with)
              (NP
                (NP (NN:[514..521] disease) (NN:[522..533] progression))
                (PP (TO:[534..536] to)
                  (NP (JJ:[537..542] acute) (NN:[543..551] leukemia)))))))
        (PRN (-LRB-:[552..553] -LRB-)
          (S
            (NP-SBJ
              (NP (CD:[553..554] 8))
              (PP (IN:[555..557] of)
                (NP (CD:[559..561] 11) (NNS:[562..570] patients))))
            (VP (SYM:[571..572] =)
              (NP (CD:[573..575] 73) (NN:[575..576] %))))
          (-RRB-:[576..577] -RRB-))))
    (.:[577..578] .)))

;sentence 6 Span:579..629
;Two general mechanisms of ras mutation were found.
;[605..608]:gene-rna:"ras"
(SENT
  (S
    (NP-SBJ-1
      (NP (CD:[579..582] Two) (JJ:[583..590] general)
          (NNS:[591..601] mechanisms))
      (PP (IN:[602..604] of)
        (NP (NN:[605..608] ras) (NN:[609..617] mutation))))
    (VP (VBD:[618..622] were)
      (VP (VBN:[623..628] found)
        (NP-1 (-NONE-:[628..628] *))))
    (.:[628..629] .)))

;sentence 7 Span:630..823
;In five  patients the ras mutation was present in only a fraction of the
;cells; sometimes  appearing in late stages of the disease, suggesting that it
;can occur in a  differentiated cell clone.
;[652..655]:gene-rna:"ras"
;[734..760]:malignancy:"late stages of the disease"
(SENT
  (S
    (PP (IN:[630..632] In)
      (NP (CD:[633..637] five) (NNS:[639..647] patients)))
    (NP-SBJ (DT:[648..651] the) (NN:[652..655] ras) (NN:[656..664] mutation))
    (VP (VBD:[665..668] was)
      (ADJP-PRD (JJ:[669..676] present)
        (PP (IN:[677..679] in)
          (NP
            (NP
              (ADVP (RB:[680..684] only))
              (DT:[685..686] a) (NN:[687..695] fraction))
            (PP (IN:[696..698] of)
              (NP (DT:[699..702] the) (NNS:[703..708] cells))))))
      (::[708..709] ;)
      (S-ADV
        (NP-SBJ (-NONE-:[709..709] *))
        (ADVP-TMP (RB:[710..719] sometimes))
        (VP (VBG:[721..730] appearing)
          (PP (IN:[731..733] in)
            (NP
              (NP (JJ:[734..738] late) (NNS:[739..745] stages))
              (PP (IN:[746..748] of)
                (NP (DT:[749..752] the) (NN:[753..760] disease)))))))
      (,:[760..761] ,)
      (S-ADV
        (NP-SBJ (-NONE-:[761..761] *))
        (VP (VBG:[762..772] suggesting)
          (SBAR (IN:[773..777] that)
            (S
              (NP-SBJ (PRP:[778..780] it))
              (VP (MD:[781..784] can)
                (VP (VB:[785..790] occur)
                  (PP-LOC (IN:[791..793] in)
                    (NP (DT:[794..795] a) (VBN:[797..811] differentiated)
                        (NN:[812..816] cell) (NN:[817..822] clone))))))))))
    (.:[822..823] .)))

;sentence 8 Span:824..929
;In six other patients, the ras mutation was present  in the great majority of
;bone marrow or blood cells.
;[851..854]:gene-rna:"ras"
(SENT
  (S
    (PP (IN:[824..826] In)
      (NP (CD:[827..830] six) (JJ:[831..836] other) (NNS:[837..845] patients)))
    (,:[845..846] ,)
    (NP-SBJ (DT:[847..850] the) (NN:[851..854] ras) (NN:[855..863] mutation))
    (VP (VBD:[864..867] was)
      (ADJP-PRD (JJ:[868..875] present)
        (PP (IN:[877..879] in)
          (NP
            (NP (DT:[880..883] the) (JJ:[884..889] great)
                (NN:[890..898] majority))
            (PP (IN:[899..901] of)
              (NP
                (NP
                  (NML (NN:[902..906] bone) (NN:[907..913] marrow))
                  (NML-1 (-NONE-:[913..913] *P*)))
                (CC:[914..916] or)
                (NP (NN:[917..922] blood)
                  (NML-1 (NNS:[923..928] cells)))))))))
    (.:[928..929] .)))

;sentence 9 Span:930..1164
;The mutation was detected  in mature normal lymphocytes and persisted
;following a complete clinical  remission in two of these patients, implying
;that the ras mutation can occur in  an early stage of cell differentiation or
;stem cell.
;[1085..1088]:gene-rna:"ras"
(SENT
  (S
    (NP-SBJ-1 (DT:[930..933] The) (NN:[934..942] mutation))
    (VP
      (VP (VBD:[943..946] was)
        (VP (VBN:[947..955] detected)
          (NP-1 (-NONE-:[955..955] *))
          (PP-LOC (IN:[957..959] in)
            (NP (JJ:[960..966] mature) (JJ:[967..973] normal)
                (NNS:[974..985] lymphocytes)))))
      (CC:[986..989] and)
      (VP (VBD:[990..999] persisted)
        (PP (VBG:[1000..1009] following)
          (NP (DT:[1010..1011] a) (JJ:[1012..1020] complete)
              (JJ:[1021..1029] clinical) (NN:[1031..1040] remission)))
        (PP-LOC (IN:[1041..1043] in)
          (NP
            (NP (CD:[1044..1047] two))
            (PP (IN:[1048..1050] of)
              (NP (DT:[1051..1056] these) (NNS:[1057..1065] patients)))))
        (,:[1065..1066] ,)
        (S-ADV
          (NP-SBJ (-NONE-:[1066..1066] *))
          (VP (VBG:[1067..1075] implying)
            (SBAR (IN:[1076..1080] that)
              (S
                (NP-SBJ (DT:[1081..1084] the) (NN:[1085..1088] ras)
                        (NN:[1089..1097] mutation))
                (VP (MD:[1098..1101] can)
                  (VP (VB:[1102..1107] occur)
                    (PP (IN:[1108..1110] in)
                      (NP
                        (NP (DT:[1112..1114] an) (JJ:[1115..1120] early)
                            (NN:[1121..1126] stage))
                        (PP (IN:[1127..1129] of)
                          (NP
                            (NP (NN:[1130..1134] cell)
                                (NN:[1135..1150] differentiation))
                            (CC:[1151..1153] or)
                            (NP (NN:[1154..1158] stem) (NN:[1159..1163] cell))))))))))))))
    (.:[1163..1164] .)))

;sentence 10 Span:1165..1381
;Patients with a ras  mutation had a median survival of nine months (all
;patients dead) compared to 16  patients without a ras mutation that had a
;median follow-up of 16 months (10  patients alive; P less than 0.005).
;[1181..1184]:gene-rna:"ras"
;[1287..1290]:gene-rna:"ras"
(SENT
  (S
    (NP-SBJ
      (NP (NNS:[1165..1173] Patients))
      (PP (IN:[1174..1178] with)
        (NP (DT:[1179..1180] a) (NN:[1181..1184] ras) (NN:[1186..1194] mutation))))
    (VP (VBD:[1195..1198] had)
      (NP
        (NP (DT:[1199..1200] a) (JJ:[1201..1207] median)
            (NN:[1208..1216] survival))
        (PP (IN:[1217..1219] of)
          (NP (CD:[1220..1224] nine) (NNS:[1225..1231] months))))
      (PRN (-LRB-:[1232..1233] -LRB-)
        (S
          (NP-SBJ (DT:[1233..1236] all) (NNS:[1237..1245] patients))
          (ADJP-PRD (JJ:[1246..1250] dead)))
        (-RRB-:[1250..1251] -RRB-))
      (S-ADV
        (NP-SBJ-2 (-NONE-:[1251..1251] *))
        (VP (VBN:[1252..1260] compared)
          (NP-2 (-NONE-:[1260..1260] *))
          (PP-CLR (TO:[1261..1263] to)
            (NP
              (NP
                (NP (CD:[1264..1266] 16) (NNS:[1268..1276] patients))
                (PP (IN:[1277..1284] without)
                  (NP (DT:[1285..1286] a) (NN:[1287..1290] ras)
                      (NN:[1291..1299] mutation))))
              (SBAR
                (WHNP-1 (WDT:[1300..1304] that))
                (S
                  (NP-SBJ-1 (-NONE-:[1304..1304] *T*))
                  (VP (VBD:[1305..1308] had)
                    (NP
                      (NP (DT:[1309..1310] a) (JJ:[1311..1317] median)
                          (VB:[1318..1324] follow) (HYPH:[1324..1325] -)
                          (RP:[1325..1327] up))
                      (PP (IN:[1328..1330] of)
                        (NP (CD:[1331..1333] 16) (NNS:[1334..1340] months))))
                    (PRN (-LRB-:[1341..1342] -LRB-)
                      (FRAG
                        (S
                          (NP-SBJ (CD:[1342..1344] 10)
                                  (NNS:[1346..1354] patients))
                          (ADJP-PRD (JJ:[1355..1360] alive)))
                        (::[1360..1361] ;)
                        (S
                          (NP-SBJ (NN:[1362..1363] P))
                          (ADJP-PRD
                            (ADJP (JJR:[1364..1368] less))
                            (PP (IN:[1369..1373] than)
                              (NP (CD:[1374..1379] 0.005))))))
                      (-RRB-:[1379..1380] -RRB-))))))))))
    (.:[1380..1381] .)))

;sentence 11 Span:1382..1657
;Since 9 of the 11 patients (82%) with a ras  mutation were found to have an
;abnormal monocytic component at diagnosis or  during disease evolution, it is
;possible that in myeloid disorders a ras  mutation is preferentially
;associated with myelomonocytic cell differentiation.
;[1422..1425]:gene-rna:"ras"
;[1553..1570]:malignancy:"myeloid disorders"
;[1573..1576]:gene-rna:"ras"
(SENT
  (S
    (SBAR-ADV (IN:[1382..1387] Since)
      (S
        (NP-SBJ-1
          (NP (CD:[1388..1389] 9))
          (PP (IN:[1390..1392] of)
            (NP
              (NP (DT:[1393..1396] the) (CD:[1397..1399] 11)
                  (NNS:[1400..1408] patients)
                (PRN (-LRB-:[1409..1410] -LRB-)
                  (NP (CD:[1410..1412] 82) (NN:[1412..1413] %))
                  (-RRB-:[1413..1414] -RRB-)))
              (PP (IN:[1415..1419] with)
                (NP (DT:[1420..1421] a) (NN:[1422..1425] ras)
                    (NN:[1427..1435] mutation))))))
        (VP (VBD:[1436..1440] were)
          (VP (VBN:[1441..1446] found)
            (S
              (NP-SBJ-1 (-NONE-:[1446..1446] *))
              (VP (TO:[1447..1449] to)
                (VP (VB:[1450..1454] have)
                  (NP (DT:[1455..1457] an) (JJ:[1458..1466] abnormal)
                      (JJ:[1467..1476] monocytic) (NN:[1477..1486] component))
                  (PP-TMP
                    (PP (IN:[1487..1489] at)
                      (NP (NN:[1490..1499] diagnosis)))
                    (CC:[1500..1502] or)
                    (PP (IN:[1504..1510] during)
                      (NP (NN:[1511..1518] disease) (NN:[1519..1528] evolution)))))))))))
    (,:[1528..1529] ,)
    (NP-SBJ (PRP:[1530..1532] it))
    (VP (VBZ:[1533..1535] is)
      (ADJP-PRD (JJ:[1536..1544] possible)
        (SBAR (IN:[1545..1549] that)
          (S
            (PP (IN:[1550..1552] in)
              (NP (JJ:[1553..1560] myeloid) (NNS:[1561..1570] disorders)))
            (NP-SBJ (DT:[1571..1572] a) (NN:[1573..1576] ras)
                    (NN:[1578..1586] mutation))
            (VP (VBZ:[1587..1589] is)
              (ADVP (RB:[1590..1604] preferentially))
              (VP (VBN:[1605..1615] associated)
                (PP-CLR (IN:[1616..1620] with)
                  (NP (JJ:[1621..1635] myelomonocytic) (NN:[1636..1640] cell)
                      (NN:[1641..1656] differentiation)))))))))
    (.:[1656..1657] .)))

;section 12 Span:1661..1705
;PMID: 2657575 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1661..1665] PMID) (::[1665..1666] :) (CD:[1667..1674] 2657575)
        (NN:[1675..1676] -LSB-) (NNP:[1676..1682] PubMed) (::[1683..1684] -)
        (NN:[1685..1692] indexed) (IN:[1693..1696] for)
        (NNP:[1697..1705] MEDLINE-RSB-)))
